Chemoprophylaxis for tuberculosis in hiv-infected individuals in sub-Saharan Africa

East African Medical Journal

Volumn 75, Issue 9, 1998, Pages 520-527

  Nuwaha, F ^a  

^a MBARARA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

TUBERCULOSTATIC AGENT;

ADULT; AFRICA SOUTH OF THE SAHARA; AIDS RELATED COMPLEX; COST BENEFIT ANALYSIS; ECONOMICS; FEASIBILITY STUDY; HUMAN; MASS SCREENING; METHODOLOGY; PATIENT COMPLIANCE; PUBLIC HEALTH SERVICE; REVIEW; TUBERCULOSIS;

ADULT; AFRICA SOUTH OF THE SAHARA; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTITUBERCULAR AGENTS; COST-BENEFIT ANALYSIS; FEASIBILITY STUDIES; HUMANS; MASS SCREENING; PATIENT COMPLIANCE; PUBLIC HEALTH PRACTICE; TUBERCULOSIS;

EID: 0032152679     PISSN: 0012835X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Reider, H.L., Cauthen, M.G., Comstock, W.G. and Snider, D.E. Epidemiology of tuberculosis in the United States, epidemiological reviews. 1990; 11:79-98.
2. Raviglione, M.C., Narain, J.P. and Kochi, A. HIV associated tuberculosis in developing countries: clinical features, diagnosis and treatment. Bull Wld. Hlth. Organ. 1992; 70:515-26.
3. Allen, S. Batungwanayo, J. and Kerliwowke, et al; Two year incidence of tuberculosis in cohorts of HIV infected and uninfected urban women. Ann. Rev. Res. Dis. 1992; 146:1439-44.
4. Edlin, B.R., Tokars, J.I. and Grieco, M.H. An outbreak of multi-drug resistant tuberculosis in among hospitalised patients with the acquired Immunodeficiency syndrome. N. Engl. J. Med. 1992; 326:1514-21.
5. Small, P.M., Shafer, R.W. and Hopewell, P.C. et al. Exogenous reinfection with multi-drug resistant tuberculosis. Mycobacterium tuberculosis in patients with advanced HIV infection. N. Engl. J. Med. 1993; 328:1137-44.
6. Barnes, P.F., Bloc, A.B., Davidson, P.T. and Snider D.E. Tuberculosis in patients with Human Immunodeficiency Virus infection. N. Engl. J. Med. 1991; 324:1644-50.
7. Haries A.D. Tuberculosis and Human immune deficiency virus in developing countries Lancet. 1990; 335:387-390.
8. AIDS Control Programme, AIDS Surveillance report, fourth quarter 1997. Ministry of Health, Entebbe, Uganda.
9. Nuwaha, F.N. Contemporary treatment of tuberculosis in high-HIV prevalent countries in sub-Saharan Africa. East. Afr. Med. J. 1998; 75:358-363.
10. Rodrigue, L.C. and Smith, P.G. Tuberculosis in developing countries and methods for it's control. Trans. roy. Soc. Trop. Med. Hyg. 1990; 84:739-44.
11. CDC. Guidelines for preventing the transmission of tuberculosis in health facilities. Morbid. Mortal. Wkly. Rev. 1994; 43(RR-13):1-32.
12. Murray, C.J.L., Styblo, K. and Rouillion, A. Tuberculosis in developing countries: burden intervention and cost, Bull IUATLD. 1990; 65:1-24.
13. WHO. Managing tuberculosis at the district level. Geneva; WHO, 1992.
14. Styblo, K. Epidemiology of tuberculosis. The Hague: Royal Netherlands Tuberculosis Association selected papers 1991, volume 24.
15. Stott, H., Patel, A. and Sutherland, I. et al. The risk of tuberculosis infection in Uganda, derived from the findings of National tuberculin surveys in 1958 and 1970. Tubercle. 1973; 54:1-24.
16. Decock, M.K., Grant, A. and Porter, J.D.H. Preventive therapy for tuberculosis in HIV-infected persons: international recommendations, research and practice. Lancet. 1995; 345:833-836.
17. Heymann, S.J. Modelling the efficacy of prophylactic and curative therapies for preventing the spread of tuberculosis in Africa. Trans. roy. Soc. Trop. Med. Hyg. 1993; 87:406-411.
18. Pape, P.W., Jena, S.S., Ho, J.L., Hafner, A. and Johnson, W.D. Jr. Effect of isoniazid prophylaxis on incidence of tuberculosis and progression of HIV infection. Lancet. 1993; 342:268-72.
19. Whalen, C.C., Johnson, J.L. and Okwera, A. et al. A trial of three regimens to prevent tuberculosis in Uganda adults infected with the Human Immunodeficiency Virus. N. Eng. J. Med. 1997; 801-808.
20. O'Brien, R.J. Preventing therapy for tuberculosis in: Porter, J.H.D., Macadam K.P.W.J. eds. Tuberculosis: Back to the future. Chichester: Wiley, 1994; 151-166.
21. Masobe, P., Lee, T. and Price, M. Isoniazid prophylactic therapy for tuberculosis in HIV-seropositive patients-a least-cost analysis. S. Afr. Med. J. 1995; 85:75-81.
22. Fereebe, S.H. Controlled chemoprophylaxis trials in tuberculosis: a general review, Advanced Tubercle Research. 1970; 17:29-106.
23. Grzybowski, S., Ashley, M.J. and Pincus, G. Chemoprophylaxis in inactive tuberculosis: long-term evaluation of a Canadian. Can. Med. Ass. J. 1976; 114:607-11.
24. Parma, S.P. and Mathur, G.P. Effects of chemoprophylaxis on minimal tuberculosis lesions of doubtful activity. Bull Wld. Hlth. Organ. 1971; 45:593-602.
25. Wadhavan, D., Hira, S., Mwansa, N., Sunkutu, R., Adera, P. and Penne P.L. Preventive tuberculosis chemotherapy with Isoniazid (INH) among patients infected with HIV-1. Ninth international conference on AIDS in affiliation with fourth STD world congress, Berlin, June 6-11, Abstr. PO-B07-1114.
26. CDC. The use of preventive therapy for tuberculous infection in the United States. Recommendations of the advisory committee forthe elimination of tuberculosis. Morbid. Mortal. Wkly. Rev. 1990; 39:9-12.
27. WHO Tuberculosis preventive therapy in HIV infected individuals. Wkly. Epidem. Rec. 1993; 68:361-8.
28. Hasley, N., Coberly, J., Atkinson, J. and Boulous, L. et al. Twice weekly INH for TB prophylaxis. Tenth conference on AIDS/ International conference on STD. Yokohama, Aug., 7-12, 1994: Abstr PB0681.
29. Selwyn, P.A., Sckell, B.M., Alcabes, P., Friedland, G.H., Klein, R.S. and Schoenbaun, E.E. High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy. J. Amer. Med. Ass. 1992; 268:504-9.
30. Guelar, A., Gatell, J.M. and Podzamcer, D. et al. A prospective study of the risk of tuberculosis among HIV infected patients. AIDS. 1993; 7:1345-9.
31. Prignot, J., Perriens, J.H. and St Louis M.E. et al Should the 2H7R7Z7 E7-4H2R2 regimen be extended for smear positive pulmonary tuberculosis in HIV-1 infected patients? 28th World Congress of IUATLD/UICTMR, Mainz, June 14-17, 1994: abstr. 3.
32. Aisu, T. Ravigilione, M.C. and Van Praag, E. et al. Preventive chemotherapy for HIV associated TB in Uganda: an operational assessment at a voluntary counselling and testing centre. AIDS. 1995; 9:267-73.
33. CDC. Severe isoniazid associated hepatitis. New York, 1991-1993. Morbid. Mortal. Wkly. Rev. 1993; 42:545-47.
34. Salpeter, S.R. Fatal isoniazid induced hepatitis: its risk during chemoprophylaxis. West A. J. Med. 1993; 159:560-64.
35. Small, P.M., Hopewell, P.C. and Singh, S.P. et al. The epidemiology of tuberculosis in San Francisco. N. Engl. J. Med. 1994; 330: 1703-09.
36. Mwinga, A., Elliot, A., Haliwindii, B., Pobee, J., Luo, N., Porter, J. and Mcadam, K.P.W.J. One year follow up of patients in a pilot study to determine the efficacy of chemoprophylaxis in the prevention of HIV related tuberculosis in Zambia. Abstract 35A, World congress or tuberculosis. November 16-19 1992, Bethesda, Maryland, USA.
37. Ngamvithayapong, J., Uthaivaravit, W., Yanai, H., Akarasewi, P. and Sawanpanyalert, P. Adherence to tuberculosis preventive therapy among HIV infected person in Chiang Rai, Thailand. AIDS. 1997; 11:107-12.
38. Duncan, L., Elliot, A. and Ebrahim, H. et al. Tuberculin sensitivity and HIV status among patients attending a sexually transmitted diseases clinic in Lusaka, Zambia, VII International Conference on AIDS, Florence Italy, 16-20 June 1991, Abstract W.C. 3104:322.
39. Okwera, A., Eriki, P.P. and Guay, L.A. et al. Tuberculin reactions in apparently health HIV seropositive and HIV seronegative women in Uganda. Morbid. Mortal. Wkly. Rev. 1990; 369:638-46.
40. Johnson, M., Cobery, J. and Clermont, H.C. et al. Tuberculin skin reactivity among adults infected with human Immunodeficiency virus. J. infectious Dis. 1992; 166: 194-98.
41. Long, R., Scahani, M. Manfreda, et al. Impact of HIV type 1 on tuberculosis in rural Haiti. Ann Rev. Res. Dis. 1991; 143:69-73.
42. Thompson, N.J., Glassroth, J.L., Snider, D.E. Jr. and Farer, L.S. The booster phenomenon in serial tuberculin testing. Ann. Rev. Res. Dis. 1979; 119:587-97.
43. CDC. Purified Protein derivative (PPD), tuberculin anergy and HIV: guidelines for anergy testing and management of anergic persons at risk of tuberculosis. Morbid. Mortal. Wkly. Rev. 1991; 40:27-32.
44. Jordan, J.T., Eugene, M.L., Montogomery, R.L. and Reichman, B.L. Isoniazid as preventive therapy in HIV infected drug abusers: a decision analysis. J. Amer. Med. Ass. 1991; 265:2987-91.
45. Hecker, M.T., Johnson, J.L., Whalen, C.C., Nyole, S. Mugerwa, R.D. and Ellner, J.J. Two step tuberculin testing in HIV-infected persons in Uganda. Amer. J. Respir. Crit. Care Med. 1997; 155: 81-6
46. Jonghe, D.E., Murray, C.J.L. Chum, H.J., Nyangulu, D.S., Salomao, A. and Styblo, K. Cost-effectiveness of chemotherapy for sputum smear-positive pulmonary tuberculosis in Malawi, Mozambique and Tanzania. Int. J. Hlth. Plan. Man. 1994; 9:151-181.
47. Barnum, H.N. Cost savings from alternative treatments for tuberculosis. Soc. Sci. Med. 1995; 40:1203-1212.
48. Nunn, P.P., Brindle, R. and Carpenterm L.M., et al. Cohort study of HIV infection in tuberculosis patients, Nairobi Kenya: analysis of early six months mortality Ann Rev. Res. Dis. 1992; 146: 849-854.
49. Foster, S. Godfrey-Fausset, P. and Porter, J. Modelling the economic benefits of tuberculosis preventive therapy for people with HIV: the example of Zambia. AIDS. 1997; 11:919-25.
50. De Cock, K.M., Lucas, S.B., Lucas, S. Agness, J., Kadio, A. and Gayle, H.D. HIV and AIDS in Africa. Research priorities should not be limited to prophylaxis. (Letter) Amer J. Public Hlth. 1994; 84:1179.
51. Espinal M.A., Reingold, A.L., Koenig, E., Lavandera, M. and Sanchez, S. Screening for active tuberculosis in HIV testing centre. Lancet. 1995; 345:890-3.
52. Nuwaha, F.N. Integrating tuberculosis control into primary health care in Uganda during the era of the HIV epidemic. J. Comprehensive Hlth. 1995; 6:46-48.